Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


13.03.2017

2 Blood
2 J Pediatr Hematol Oncol
2 Leuk Lymphoma
1 N Engl J Med
2 Oncol Rep
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Blood

  1. RAHMAN S, Magnussen M, Leon TE, Farah N, et al
    Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.
    Blood. 2017 Mar 7. pii: blood-2016-09-742148. doi: 10.1182/blood-2016-09-742148.
    PubMed     Text format     Abstract available

  2. LAL R, Lind K, Heitzer E, Ulz P, et al
    Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.
    Blood. 2017 Mar 3. pii: blood-2016-11-751008. doi: 10.1182/blood-2016-11-751008.
    PubMed     Text format    


    J Pediatr Hematol Oncol

  3. ARIKAN K, Ozsurekci Y, Ceyhan M
    Bullous Pyoderma Gangrenosum as the Presenting Sign of Acute Myeloid Leukemia in a Child.
    J Pediatr Hematol Oncol. 2017 Mar 6. doi: 10.1097/MPH.0000000000000796.
    PubMed     Text format    

  4. ARIKAN K, Ozsurekci Y, Ceyhan M
    Bullous Pyoderma Gangrenosum as the Presenting Sign of Acute Myeloid Leukemia in a Child.
    J Pediatr Hematol Oncol. 2017 Mar 6. doi: 10.1097/MPH.0000000000000795.
    PubMed     Text format    


    Leuk Lymphoma

  5. CHAOUI D, Choquet S, Sanhes L, Mahe B, et al
    Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
    Leuk Lymphoma. 2017;58:1366-1375.
    PubMed     Text format     Abstract available

  6. HANDUNNETTI SM, Polliack A, Tam CS
    Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?
    Leuk Lymphoma. 2017;58:1281-1282.
    PubMed     Text format    


    N Engl J Med

  7. HOCHHAUS A, Larson RA, Guilhot F, Radich JP, et al
    Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
    N Engl J Med. 2017;376:917-927.
    PubMed     Text format     Abstract available


    Oncol Rep

  8. LI Y, Zhao L, Li N, Miao Y, et al
    miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
    Oncol Rep. 2017 Feb 17. doi: 10.3892/or.2017.5464.
    PubMed     Text format     Abstract available

  9. TOMAN O, Kabickova T, Vit O, Fiser R, et al
    Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.
    Oncol Rep. 2016;36:1258-68.
    PubMed     Text format     Abstract available


    PLoS One

  10. LI Y, Liu S, Wang H, Mai H, et al
    Methylation level of CpG islands in GGH gene promoter in pediatric acute leukemia.
    PLoS One. 2017;12:e0173472.
    PubMed     Text format     Abstract available

  11. GARCIA-GUTIERREZ V, Gomez-Casares MT, Puerta JM, Alonso-Dominguez JM, et al
    A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
    PLoS One. 2017;12:e0173532.
    PubMed     Text format     Abstract available

  12. LIN TY, Chen KC, Liu HE, Liu AJ, et al
    Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    PLoS One. 2017;12:e0173828.
    PubMed     Text format     Abstract available

  13. HOCK BD, MacPherson SA, McKenzie JL
    Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
    PLoS One. 2017;12:e0172858.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: